Literature DB >> 404156

Immunoglobulins in myasthenia gravis: effect of human lymph IgG 3 and F (ab')2 fragments on a cholinergic receptor preparation from Torpedo marmorata.

A K Lefvert, K Bergström.   

Abstract

Lymph IgG from patients with myasthenia gravis was shown to inhibit the binding of radio-labelled Naja naja siamensis alpha-neurotoxin to membrane fragments from the electric organ of Torpedo marmorata. This effect could be related to IgG subclass 3 and to the F(ab')2 fragment. These findings confirm the involvement of antibodies of postsynaptic structures in myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404156     DOI: 10.1111/j.1365-2362.1977.tb01582.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

Authors:  A K Lefvert; K Bergström; G Matell; P O Osterman; R Pirskanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

3.  Immunoglobulins in myasthenia gravis. Kinetic properties of the acetylcholine-receptor antibody studied during lymph drainage.

Authors:  A K Lefvert
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

4.  IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies.

Authors:  L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

5.  IgG subclass distribution in organ specific autoantibodies. The relationship to complement fixing ability.

Authors:  B M Dean; G F Bottazzo; A G Cudworth
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

6.  IgG subclass distribution of antibodies against S. aureus teichoic acid and alpha-toxin in normal and immunodeficient donors.

Authors:  L Hammarström; M Granström; V Oxelius; M A Persson; C I Smith
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

7.  Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.

Authors:  B Vernet-der Garabedian; J F Bach; E Morel
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

8.  Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm.

Authors:  R A Eisenberg; K Dyer; S Y Craven; C R Fuller; W J Yount
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

9.  Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors.

Authors:  B W Fulpius; R Miskin; E Reich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  Association between thyroid microsomal antibodies of subclass IgG-1 and hypothyroidism in autoimmune postpartum thyroiditis.

Authors:  R Jansson; P M Thompson; F Clark; S M McLachlan
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.